Pugatch Consilium at the New Delhi conference on Expanding Healthcare Access in India

Posted by:

Last thursday January 14, 2016, Prof Meir Pugatch spoke at the groundbreaking conference entitled “Growing the Innovative Bio-pharmaceutical Industry and Expanding Healthcare Access in India” in New Delhi convened by the The U.S.-India Business Council (USIBC) in partnership with the Department of Industrial Policy and Promotion (DIPP) and the Investment and Technology Promotion Division (ITP) of the Ministry of External Affairs. During the session, Prof Pugatch presented the findings of one of Pugatch Consilium’s latest studies on India, highlighting how ...

Continue Reading →
0

The Next Frontier in Ensuring the Quality of Medicines: Maintaining International Quality and Safety Standards in the Manufacturing and Supply of Active Pharmaceutical Ingredients

Posted by:

Today Pugatch Consilium launches The Next Frontier in Ensuring the Quality of Medicines: Maintaining International Quality and Safety Standards in the Manufacturing and Supply of Active Pharmaceutical Ingredients. Authored by Professor Meir Pugatch, Dr. David Torstensson and Ma’ayan Laufer this report provides a deep-dive analysis of the next generation of challenges facing drug regulators across the globe.

Pharmacovigilance is the name given to the mechanisms and tests that together map and ensure the safety of a medicine throughout its life span ...

Continue Reading →
0

Pugatch Consilium at the International BIO Convention

Posted by:

Yesterday, June 16th 2015, Prof Meir Pugatch presented the findings of two of Pugatch Consilium’s latest studies at an opening plenary session of the International BIO Convention in Philadelphia, Pennsylvania. During the session, Prof Pugatch discussed empirical measures of national biopharmaceutical environments, including the Biopharmaceutical Competitiveness & Investment (BCI) Survey and Building the Bioeconomy 2015, and how these tools can be used to shed light on emerging opportunities and challenges in global biotech markets.

 

The results of the two studies are also being presented in additional panels ...

Continue Reading →
0

New Study: Policy Environment Has a Significant Impact on Biopharmaceutical Investment

Posted by:

Economies’ policy trajectories have a significant impact on biopharmaceutical investment decisions, perhaps more than costs and market size, according to local executives. Our new study, Measuring the Global Biomedical Pulse: The Biopharmaceutical Investment & Competitiveness (BCI) Survey, finds that economies with policy environments that support investment and innovation rank as the most attractive for biopharmaceutical investment in the eyes of top level executives operating on the ground. The study, commissioned by PhRMA, also finds that notwithstanding low costs and considerable ...

Continue Reading →
0

PUGATCH CONSILIUM LAUNCHES NEW REPORT ON BUILDING THE BIOECONOMY

Posted by:

Today Pugatch Consilium launches Building the Bioeconomy 2015 the second edition study of the policies and best practices that pave the way for a creating an environment and ecosystem that enables biotech innovation. The 2015 edition focuses on 13 countries: Brazil, China, India, Korea, Malaysia, Mexico, Russia, Singapore, South Africa, Switzerland, Turkey, the UK and the United States. Using a comparative perspective and looking in detail at the country specific-level, the report identifies several important findings as well as lessons learned.

 

The report identifies ...

Continue Reading →
0

The Evolution of Pharmacovigilance: Labeling, Packaging and Pharmacopeia Standards

Posted by:

Today Pugatch Consilium launches The Evolution of Pharmacovigilance: Labeling, Packaging and Pharmacopeia Standards. Authored by Professor Meir Pugatch, Dr David Torstensson and Ma’ayan Laufer this report provides a deep-dive analysis of the next generation of challenges facing pharmacoviglance regulators.

Pharmacovigilance is the name given to the mechanisms and tests that together map and ensure the safety of a medicine throughout its life span – from test tube to patient. As patients and healthcare professionals around the world access and use more ...

Continue Reading →
0

Clinical Data and Disclosure Policies

Posted by:

Pugatch Consilium, in partnership with the US Chamber’s Global Intellectual Property Center, releases Clinical Data and Disclosure Policies: The European Union, Member States, and International Best Practices. This report provides an exhaustive analysis of the clinical data transparency aspects of EU Parliament Regulation 536/2014 on clinical trials and EMA’s finalized policies on Publication and Access to Clinical Trials Data, as well as a review of the wider policy implications and interface of these policies vis-á-vis current data disclosure policies at ...

Continue Reading →
0

How to Stay One Step Ahead of an Outbreak

Posted by:

Pugatch Consilium’s Prof. Meir Pugatch and Rachel Chu publish an article in fDi Magazine (http://www.fdiintelligence.com/) on how building an innovation culture can help countries prepare for the outbreak of diseases such as Ebola. The article is part of Pugatch Consilium’s ongoing analysis and intelligence database on biopharmaceutical investment and innovation policy.

How to stay one step ahead of an outbreak  – Read more on our Research & Analysis Reports Page

Continue Reading →
0
Page 4 of 14 «...23456...»